|
|
News Breaks | | | | February 20, 2013 | | 04:55 EDT |  | A, A, A, A, RHHBY, RHHBY, RHHBY, RHHBY, PKI, PKI, PKI, PKI, LIFE, LIFE, LIFE, LIFE, ILMN, ILMN, ILMN, ILMN, QGEN, QGEN, QGEN, QGEN, PACB, PACB, PACB, PACB | G Corp to host a meeting
14th Annual Advances in Genome Biology and Technology Meeting is being held on Marco Island, Florida on February 20-23. | |
|
News For A;RHHBY;PKI;LIFE;ILMN;QGEN;PACB From The Last 14 Days Check below for free stories on A;RHHBY;PKI;LIFE;ILMN;QGEN;PACB the last two weeks. |
|
|
| June 13, 2013 | | 11:02 EDT | | RHHBY | Leerink's major pharma analyst holds an analyst/Industry conference call
 Subscribe for More Information | | | 08:01 EDT |  | LIFE | Life Technologies acquires Life Science Korea
Subscribe for More Information | | | June 11, 2013 | | 13:34 EDT |  | LIFE | Options with increasing implied volatility: EBIX LIFE SFD
| | | 08:01 EDT | | RHHBY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information | | | June 10, 2013 | | 11:57 EDT | | LIFE | Options with increasing implied volatility: WM LIFE
| | | 07:40 EDT | | RHHBY | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | 07:24 EDT | | RHHBY, ILMN | European Society of Human Genetics to host a conference
Subscribe for More Information | | | 06:42 EDT |  | ILMN | Illumina removed from U.S. Focus List at Credit Suisse
Subscribe for More Information | | | June 7, 2013 | | 12:04 EDT | | LIFE | Options with increasing implied volatility:TIBX RHT IRM CA LIFE
Subscribe for More Information | | | 07:26 EDT | | QGEN | QIAGEN expands offering of assay panels for next-generation sequencing
Subscribe for More Information | | | | June 6, 2013 | | 15:11 EDT | | QGEN | QIAGEN affirms FY13 view after Quest Diagnostics, Hologic strike deal
QIAGEN (QGEN) said its full-year earnings view will not be changed following an announcement that Quest Diagnostics (DGX) and Hologic (HOLX) reached a supply agreement. WHAT'S NEW: Earlier today, Quest Diagnostics and Hologic announced a non-exclusive agreement for Quest to more broadly offer Hologic's APTIMA family of testing products. Hologic's APTIMA line includes FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas vaginalis. WHAT'S NOTABLE: Following the announcement, QIAGEN, which competes with Hologic in the diagnostic product space, said that a "U.S. reference laboratory customer" of its products made public a deal to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN said the customer would continue to offer its HPV-related products as well. QIAGEN said that it saw no need to revise its full-year 2013 guidance based on the development. The company also noted that sales related to this development represent less than 2% of the company's anticipated 2014 sales, and HPV screening in the U.S. is expected to represent less than 10% of the company's 2014 total net sales. PRICE ACTION: Hologic advanced following news of its agreement with Quest, and its shares are up over 2% in afternoon trade. QIAGEN shares are off their best levels, but still higher by about 0.5%. | | | 14:33 EDT | | QGEN | QIAGEN says U.S. reference lab decision will not change FY13 outlook
QIAGEN announced that a U.S. reference laboratory customer of its HPV-related products used for cervical cancer screening has made public on June 6 a new non-exclusive agreement to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN has been informed that its HPV-related products will continue to be offered by this customer. QIAGEN sees no need at this time to revise its guidance for FY13, and expects that sales related to this development represent less than 2% of its anticipated total net sales for FY14. QIAGEN further expects that sales related to products used in HPV screening in the U.S. to represent less than 10% of total net sales in FY14. | | | 08:38 EDT | | LIFE | Thermo Fisher financing slightly higher than expected, says Leerink
Leerink says Thermo Fisher's (TMO) common stock offering of $2.5B to fund the Life Technologies (LIFE) deal came in slightly above its expectation of $2.1B. Further, the firm believes the second request for information from the FTC is not a surprise, and feels any required divestitures will not materially impact the financial profile of the combined company. Leerink keeps an Outperform rating on shares of Thermo Fisher. | | | 08:31 EDT | | LIFE | Thermo Fisher expects second FTC request over Life deal
Thermo Fisher (TMO) disclosed last night that it anticipates receiving on June 7, a request for additional information and documentary material, often referred to as a "Second Request," from the United States Federal Trade Commission in connection with the FTC’s Hart-Scott-Rodino regulatory review of its Life Technologies (LIFE) acquisition. The company added that it has been working, and will continue to work, cooperatively with the FTC and that it continues to expect the acquisition to close in early 2014. | | | June 5, 2013 | | 18:48 EDT | | LIFE | On The Fly: After Hours Movers
Subscribe for More Information | |
|
|
|
|
|
|
